StockData
Champions Oncology, Inc. logo

Champions Oncology, Inc. (CSBR) stock

CSBRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends April 30
Số liệu tài chính tới Q1 năm tài chính 2027, quý kết thúc ngày Jul 31, 2026Last filing: 10-Q on Sep 11, 2026Score 10/30238% above fair value
$4.44−0.15 (-3.30%)

Close on Nov 18, 2026Market cap $61.80MP/E –Yield –

Champions Oncology pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Champions Oncology's pe ratio was 35.0× on Feb 27, 2026, against 465.0× a year earlier. Over the last 3 years it ranged from 13.3× to 977.0×, with a median of 250.0×.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Feb 27, 202635.0×−5.6
2025Dec 31, 202540.6×−424.4
2023Feb 28, 2023465.0×+14.0
2022Dec 30, 2022451.0×+172.3
2021Dec 31, 2021278.7×−261.3
2019Aug 30, 2019540.0×–

More Champions Oncology figures

See a number that looks wrong?